Upstream Bio, Inc. (NASDAQ:UPB)
| Market Cap | $152.38M-89.2% |
| Revenue (ttm) | $2.87M+2.5% |
| Net Income | -$163.94M-34.1% |
| EPS | -$3.02-31.9% |
| Shares Out | 54.81M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 891,334 |
| Open | $2.94 |
| Previous Close | $2.86 |
| Day's Range | $2.73 - $2.98 |
| 52-Week Range | $2.68 - $33.68 |
| Beta | 1.39 |
| Analysts | Buy |
| Price Target | $25.00(+799.28%) |
| Earnings Date | Mar 17, 2027 |
About UPB
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating UPB in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 17, 2027Earnings report
$UPB stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in UPB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by UPB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
UPB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
UPB Revenue by Segment
| Verekitug program | $8.98M | 53.07% |
| Manufacturing costs | $2.83M | 16.69% |
| Professional fees and other | $2.01M | 11.87% |
| Professional fees | $1.64M | 9.70% |
| Other | $1.07M | 6.34% |
| Collaboration revenue | $395.00K | 2.33% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New UPB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to UPB from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in UPB
| VTIVanguard Morningstar Total Stock Market ETF | $7.60M |
| IWMiShares Russell 2000 ETF | $2.64M |
| VXFVanguard Extended Market ETF | $2.47M |
| VTWOVanguard Russell 2000 ETF | $1.17M |
| IWNiShares Russell 2000 Value ETF | $1.04M |
| IBBiShares Biotechnology ETF | $791.55K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from UPB’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 loss with revenue miss dominates coverage; one positive note on progress insufficient to offset disappointing financial results.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BBC | Virtus Biotech Clinical Trials ETF | 0.39% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.10% |
| FFSM | Fidelity Fundamental Small-Mid Cap ETF | 0.04% |
| FSMO | Fidelity Fundamental Small-Mid Cap ETF | 0.04% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.01% |
| IBB | iShares Biotechnology ETF | 0.01% |
| BIB | ProShares Ultra Nasdaq Biotechnology | 0.01% |
| VHT | Vanguard Health Care ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
